Zosano Pharma Corporation (ZSAN) Upgraded to Sell by ValuEngine

ValuEngine upgraded shares of Zosano Pharma Corporation (NASDAQ:ZSAN) from a strong sell rating to a sell rating in a research report released on Friday.

Zosano Pharma Corporation (NASDAQ ZSAN) opened at 0.9278 on Friday. The firm’s 50-day moving average is $1.05 and its 200 day moving average is $1.54. Zosano Pharma Corporation has a 52-week low of $0.45 and a 52-week high of $3.54. The company’s market cap is $36.40 million.

Zosano Pharma Corporation (NASDAQ:ZSAN) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.02. During the same quarter in the previous year, the business earned ($0.54) EPS. On average, equities research analysts predict that Zosano Pharma Corporation will post ($0.79) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://ledgergazette.com/2017/09/05/zosano-pharma-corporation-zsan-upgraded-to-sell-by-valuengine.html.

Several hedge funds have recently made changes to their positions in the company. Northern Trust Corp boosted its position in shares of Zosano Pharma Corporation by 591.4% during the 2nd quarter. Northern Trust Corp now owns 79,234 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 67,774 shares during the last quarter. Granite Point Capital Management L.P. acquired a new position in shares of Zosano Pharma Corporation during the 1st quarter valued at about $285,000. Vanguard Group Inc. boosted its position in shares of Zosano Pharma Corporation by 20.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,217,323 shares of the biotechnology company’s stock valued at $1,716,000 after acquiring an additional 209,251 shares during the last quarter. Victory Capital Management Inc. acquired a new position in shares of Zosano Pharma Corporation during the 1st quarter valued at about $449,000. Finally, Nexthera Capital LP acquired a new position in shares of Zosano Pharma Corporation during the 1st quarter valued at about $950,000. 22.66% of the stock is currently owned by hedge funds and other institutional investors.

About Zosano Pharma Corporation

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Zosano Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply